IP Library Granted Patent US 10,583,185
Granted Patent B2
US 10,583,185 · App. 15/754,867 · Granted Mar 10, 2020

Methods and compositions for immune protection against extra-intestinal pathogenic

Inventors: Jan Theunis Poolman (Haarlem, NL); Bert Jacquemyn (Mechelen, BE); Darren Robert Abbanat (Cornwall, NY); Patricia Ibarra Yon (Solothurn, CH); Peter Wilhelmus Maria Hermans (Huissen, NL); Michael Thomas Kowarik (Zurich, CH); Michael Lukas Wetter (Zurich, CH); Stefan Jochen Kemmler (Zurich, CH); Micha Andres Häuptle (Zurich, CH); Veronica Gambillara Fonck (Meilen, CH); Manuela Mally (Watt, CH)
Assignees: GlaxoSmithKline Biological S.A.; Janssen Pharmaceuticals, Inc.
A61K39/0258A61K39/385A61K47/646A61K47/6415A61P31/04C08B37/0063A61K2039/545A61K2039/55583A61K2039/6037A61K2039/6087A61K2039/70Y02A50/474
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,185
App. No.
15/754,867
Granted
Mar 10, 2020
Kind
B2
Abstract

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Claims (33)

1. A composition comprising a first concentration of an E. coli O 25B antigen polysaccharide, and a second concentration of each of an E. coli O1A antigen polysaccharide, an E. coli O2 antigen polysaccharide and an E. coli O6A antigen polysaccharide, wherein the ratio of the first concentration to the second concentration is 2:1, each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are independently covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein, and the first concentration is 10 to 36 μg/ml.

2. The composition of claim 1 , comprising the E. coli O25B, O1A, O2 and O6A antigen polysaccharides at a weight ratio of 2:1:1:1, wherein the first concentration is 10, 16, 24, 32 or 36 μg/ml.

3. The composition of claim 1 , comprising 16 μg/ml of the E. coli O 25B antigen polysaccharide.

4. The composition of claim 1 , comprising 32 μg/ml of the E. coli O 25B antigen polysaccharide.

5. A multivalent immune composition comprising an E. coli O25B antigen polysaccharide having the structure of Formula O25B′:

an E. coli O1A antigen polysaccharide having the structure of Formula O1A′:

an E. coli O2 antigen polysaccharide having the structure of Formula O2′:

and

an E. coli O6A antigen polysaccharide having the structure of Formula O6A′:

wherein n is independently an integer of 5 to 25, and

each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are independently covalently bound to a carrier protein having the amino acid sequence of SEQ ID NO:1; and

the concentrations of the E. coli O25B, O1A, O2, O6A antigen polysaccharides in the composition are respectively 16:8:8:8 μg/ml or 32:16:16:16 μg/ml.

6. A method of inducing an immune response to extra-intestinal pathogenic E. coli (ExPEC) in a subject, comprising administering to the subject the composition of claim 1 .

7. A method of inducing an immune response to extra-intestinal pathogenic E. coli (ExPEC) in a subject, comprising administering to the subject a first effective amount of an E. coli O25B antigen polysaccharide, and a second effective amount of each of an E. coli O1A antigen polysaccharide, an E. coli O2 antigen polysaccharide and an E. coli O6A antigen polysaccharide, wherein the ratio of the first effective amount to the second effective amount is 2:1, each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are independently covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein, and the first effective amount is 5 to 18 μg per administration.

8. The method of claim 7 , wherein the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are administered at a dosage ratio of 2:1:1:1, wherein the first effective amount is 6, 8, 10, 12, 14, 16, or 18 μg per administration.

9. The method of claim 7 , wherein 8 μg of the E. coli O25B antigen polysaccharide is administered per administration.

10. The method of claim 7 , wherein 16 μg of the E. coli O25B antigen polysaccharide is administered per administration.

11. The method of claim 7 , wherein the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are administered together in one composition.

12. The method of claim 7 , wherein the E. coli O25B antigen polysaccharide has the structure of Formula O25B′:

the E. coli O1A antigen polysaccharide has the structure of Formula O1A′:

the E. coli O2 antigen polysaccharide has the structure of Formula O2′:

and

the E. coli O6A antigen polysaccharide has the structure of Formula O6A′:

wherein n is independently an integer of 5 to 25,

each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are independently covalently bound to a carrier protein having the amino acid sequence of SEQ ID NO:1, and the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are administered at 8:4:4:4 μg or 16:8:8:8 μg per administration.

13. The method of claim 6 , wherein the subject has or is at risk of having an invasive ExPEC disease.

14. The method of claim 13 , wherein invasive ExPEC disease is selected from the group consisting of urinary tract infection, a surgical-site infection, an abdominal or pelvic infection, pneumonia, nosocomial pneumonia, osteomyelitis, cellulitis, sepsis, bacteremia, a wound infection, pyelonephritis, meningitis, neonatal meningitis, peritonitis, cholangitis, soft-tissue infections, pyomyositis and septic arthritis.

15. A method of inducing an immune response to extra-intestinal pathogenic E. coli (ExPEC) in a subject, comprising administering to the subject the multivalent immune composition of claim 5 .

16. The method of claim 15 , wherein the subject has or is at risk of having an invasive ExPEC disease.

17. A process of making the composition of claim 1 , comprising combining the E. coli O25B antigen polysaccharide, the E. coli O1A antigen polysaccharide, the E. coli O2 antigen polysaccharide and the E. coli O6A antigen polysaccharide to thereby obtain the composition, wherein each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides is independently covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein.

18. A process of making the multivalent immune composition of claim 5 , comprising combining the E. coli O25B antigen polysaccharide, the E. coli O1A antigen polysaccharide, the E. coli O2 antigen polysaccharide and the E. coli O6A antigen polysaccharide to thereby obtain the multivalent immune composition, wherein each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides is independently covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein.

19. The composition of claim 1 , wherein each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides independently covalently bound to the carrier protein is a bioconjugate.

20. The multivalent immune composition of claim 5 , wherein each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides independently covalently bound to the carrier protein is a bioconjugate.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: KOWARIK, MICHAEL THOMAS; WETTER, MICHAEL LUKAS; KEMMLER, STEFAN JOCHEN; HÄUPTLE, MICHA ANDRES; GAMBILLARA, VERONICA; MALLY, MANUELA
To: GLYCOVAXYN AG
Reel/Frame 051223/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: GLYCOVAXYN AG
To: GLAXOSMITHKLINE BIOLOGICALS S.A.
Reel/Frame 051223/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: POOLMAN, JAN THEUNIS; HERMANS, PETER WILHELMUS MARIA
To: CRUCELL HOLLAND B.V.
Reel/Frame 051223/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: JACQUEMYN, BERT
To: JANSSEN INFECTIOUS DISEASES & DIAGNOSTICS BVBA
Reel/Frame 051223/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: ABBANAT, DARREN ROBERT
To: JANSSEN RESEARCH & DEVELOPMENT L.L.C.
Reel/Frame 051224/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: IBARRA YON, PATRICIA
To: CRUCELL SWITZERLAND AG
Reel/Frame 051224/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: CRUCELL HOLLAND B.V.
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 051224/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: JANSSEN INFECTIOUS DISEASES & DIAGNOSTICS BVBA
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 051224/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: JANSSEN RESEARCH & DEVELOPMENT L.L.C.
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 051224/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: CRUCELL SWITZERLAND AG
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 051224/0557 →
Continuity (3)
Provisional Application 62209091 · Aug 24, 2015
Provisional Application 62210655 · Aug 27, 2015
Related Publication 20180243393A1 · Aug 30, 2018
Cited By (4)
US 12,214,029 US 12,233,118 US 12,233,121 US 12,274,742